ALMU vs NBIX · rev $4.7M vs P/E 45, rev $1.77B
Aeluma, Inc. Common Stock (ALMU) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Aeluma, Inc. Common Stock (ALMU) is a semiconductors company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ALMU revenue for 2025-06-30 was $4.7M. Net income was $3.0M. ALMU currently screens at market cap $243.1M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ALMU currently screens at market cap $243.1M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ALMU and NBIX stock pages for the full models.
Not investment advice.